Drug Profile
Research programme: oxazolidinone antibacterials - Durata
Alternative Names: PF-00422602; PF-00708093; PF-02341752; PF-987296; VIC-104742; VIC-104988; VIC-105277; VIC-105491; VIC-105518; VIC-105535; VIC-105836; VIC-106632; VIC-106675; VIC-106699; VIC-106734; VIC-106814; VIC-106822; VIC-106828; VIC-106841; VIC-106857; VIC-106871; VIC-106922; VIC-106935; VIC-106936; VIC-106976; VIC-106993; VRC-104203; VRC-104766; VRC-104811; VRC-3783; VRC-4104; VRC-4203; VRC-4530; VRC-4766; VRC-4811Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pharmacia Corporation; Vicuron Pharmaceuticals
- Developer Pfizer
- Class Oxazolidinones
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Gram-positive infections